The India condom market reached around USD 861.30 Million in 2024. The market is projected to grow at a CAGR of 11.20% between 2025 and 2034 to reach nearly USD 2.49 billion by 2034.
Between 2018 and 2023, the sale of premium condoms in India grew steadily at an annual rate of 21%. World Bank suggests that the per capita GDP of India crossed $2000 in 2021, which indicates significant potential for contraceptive products among consumers. Innovative marketing strategies that promote condom usage in local languages are garnering significant appeal among rural people. Rising social media usage and evolving attitudes towards sex are expected to play a critical role in driving the market expansion.
Since feminine contraceptives are preferred by numerous couples, the demand for panty condoms is expected to surge significantly and drive the market growth in the forecast period.
India Condom Market Growth
Condoms play an instrumental role in preventing sexually transmitted diseases and enabling people to exercise their reproductive rights. Condoms can enable 9.5% of couples in India to fulfil their unmet needs. As per the Guttmacher Institute, India witnessed 485 lakh pregnancies between 2015 and 2019, 44% of which were unintended. Nearly 2/3rd of these pregnancies ended up in unplanned abortions. It is estimated that adequate access to India's family planning services among people can minimise risk to maternal and infant health by 25% and 20% respectively. Besides, it can also prevent high-risk pregnancies by 20%-30%. This is expected to accelerate the adoption of condoms among consumers.Between 2018 and 2023, the sale of premium condoms in India grew steadily at an annual rate of 21%. World Bank suggests that the per capita GDP of India crossed $2000 in 2021, which indicates significant potential for contraceptive products among consumers. Innovative marketing strategies that promote condom usage in local languages are garnering significant appeal among rural people. Rising social media usage and evolving attitudes towards sex are expected to play a critical role in driving the market expansion.
Since feminine contraceptives are preferred by numerous couples, the demand for panty condoms is expected to surge significantly and drive the market growth in the forecast period.
India Condom Industry Segmentation
India Condom Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:Market Breakup by Type:
- Latex
- Non-Latex
Market Breakup by End User:
- Men
- Women
Market Breakup by Distribution Channel:
- Hypermarkets/Supermarkets
- Chemist Shops
- Online Channels
- Others
Market Breakup by Region:
- East India
- West India and Central India
- North India
- South India
India Condom Market Share
Based on region, the market is segmented into east India, west India and Central India, North India, and South India. East India is projected to dominate the market, representing 22% of the overall market share. Over the forecast period of 2025-2034, South India is expected to grow at a CAGR of 12.8%, due to rising consumer awareness regarding family planning.Leading Companies in the India Condom Market
Increasing consumer demand for non-latex condoms is expected to promote the manufacturing of plant-based eco-friendly condoms. The installation of point-of-sale condom dispensers at accessible places (including pharmacies) is expected to play a critical role in removing the social and psychological stigma associated with condom usage and driving the market growth.- TTK Healthcare Limited
- HLL Lifecare Limited
- Mankind Pharma Ltd.
- Reckitt Benckiser Group PLC
- Others
Table of Contents
1 Executive Summary
2 Market Overview and Stakeholder Insights
3 Economic Summary
4 Country Risk Profiles
5 Asia Pacific Condom Market Overview
6 India Condom Market Overview
7 India Condom Market by Type
8 India Condom Market by End User
9 India Condom Market by Distribution Channel
10 India Condom Market by Region
11 Market Dynamics
12 Competitive Landscape
Companies Mentioned
- TTK Healthcare Limited
- HLL Lifecare Limited
- Mankind Pharma Ltd.
- Reckitt Benckiser Group PLC